How does the POSEIDON meta-analysis results influence your decision on which patients should receive hormone therapy with post-operative radiotherapy for recurrent prostate cancer?

POSEIDON is another landmark analysis from the MARCAP consortium. It adds to the seminal work performed in localized prostate cancer (Kishan et al., PMID 35051385), which serves as the reference study for the use and duration of ADT with radiotherapy, but now in the post-prostatectomy setting.

The st...

While I may be in the minority, I am happy to play devil's advocate:

While POSEIDON is instructive and provocative, I believe that RTOG 0534 (SPPORT) is the highest quality phase III data that we have, and I currently use this data (~1,800 patients) to help guide discussions with patients.

RTOG 0534 u...